Jeffrey D Way

US Patent:

20220282263, Sep 8, 2022

Filed:

May 14, 2020

Appl. No.:

17/611010

Inventors:

- San Francisco CA, US
Alexis Rovner - San Francisco CA, US
George Church - Brookline MA, US
Jeffrey Way - San Francisco CA, US
Pamela Silver - San Francisco CA, US

International Classification:

C12N 15/70
C12N 1/20
C12N 15/67

Abstract:

Provided herein are methods of generating engineered organisms with targeted genome designs, such as recoding designs, and targeted functional properties. Also provided are methods of generating biomanufacturing engineered organisms and uses thereof for production of biomanufactured products.

US Patent:

20220228104, Jul 21, 2022

Filed:

May 14, 2020

Appl. No.:

17/611005

Inventors:

- San Francisco CA, US
Alexis Rovner - San Francisco CA, US
George Church - Brookline MA, US
Jeffrey Way - San Francisco CA, US
Pamela Silver - San Francisco CA, US

International Classification:

C12N 1/20
G16B 5/00
G16B 40/20
C12N 15/70
C12N 15/90

Abstract:

Provided herein are engineered organism containing a transgene in which expression of the transgene in an open environment is prevented or reduced, for example, by recoding designs. Also provided are methods of producing such engineered organism and use of such engineered organisms as therapeutics or for producing food, food supplement, and animal feed products.

US Patent:

20230038638, Feb 9, 2023

Filed:

Jun 14, 2021

Appl. No.:

17/347442

Inventors:

- South San Francisco CA, US
Brajesh KUMAR - Fremont CA, US
Tom KNUDSEN - Burlingame CA, US
Jan Kristian JENSEN - Randers, DK
Emil OLDENBURG - Aarhus, DK
Christine René SCHAR - Randers, DK
Matthew John TRAYLOR - Boulder CO, US
Eric Steven FURFINE - Lincoln MA, US
Jeffrey Charles WAY - Cambridge MA, US
Agnieszka JENDROSZEK - Risskov, DK
Arzu SANDIKCI - Berkeley CA, US
Jim MCGUIRE - South San Francisco CA, US
Shyam Rajan IYER - Woodside CA, US
Natacha LE MOAN - South San Francisco CA, US

International Classification:

C12N 9/64

Abstract:

Provided herein are Complement Factor I (CFI) variants that exhibit at least one improved characteristic relative to a wild type CFI. CFI variants of the disclosure can exhibit tunable specificity and activity. Also included are CFI-containing fusion constructs comprising at least one domain of CFI, for example, wild type full length CFI fused to human serum albumin. Also included are methods of making and using such CFI variants and fusion constructs. The CFI variants and fusion constructs provided herein may be useful for treating a disease or condition associated with dysregulation of the complement system or a deficiency of CFI.

US Patent:

20210222143, Jul 22, 2021

Filed:

Jan 3, 2020

Appl. No.:

16/734256

Inventors:

- South San Francisco CA, US
Christopher Thanos - Tiburon CA, US
Vanessa Soros - San Francisco CA, US
Mikhail Popkov - San Diego CA, US
Kimberly Tipton - Boston MA, US
Matthew John Traylor - Boulder CO, US
Eric Steven Furfine - Lincoln MA, US
Jeffrey Charles Way - Cambridge MA, US

International Classification:

C12N 9/72
C07K 14/765

Abstract:

Provided are u-PA polypeptides and fusion proteins containing the u-PA polypeptides. The u-PA polypeptides are modified to have altered activity and/or specificity so that they cleave a complement protein, such as complement protein C3, to thereby inhibit complement activation. The modified u-PA polypeptides and fusion proteins that inhibit complement activation can be used for treatment of diseases and conditions that are mediated by complement activation, or in which complement activation plays a role. These disorders include ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, diabetic retinopathies, age-related macular degeneration, transplanted organ rejection, inflammatory diseases and diseases with an inflammatory component.